Literature DB >> 16000672

Acute akathisia associated with quetiapine use.

Glenn Catalano1, John W Grace, Maria C Catalano, Miguel J Morales, Laura M Cruse.   

Abstract

Because of their better side-effect profile, atypical antipsychotic agents have replaced conventional antipsychotic agents as the first-line treatment for schizophrenia. Although atypical agents are less likely to be associated with extrapyramidal symptoms, such symptoms sometimes do occur in patients treated with atypical agents. The authors report the cases of two patients who developed akathisia after treatment with quetiapine for insomnia, consider previously reported cases of akathisia induced by atypical antipsychotic agents, discuss other medications that can induce similar symptoms, discuss treatments for akathisia, and examine issues in the use of quetiapine as a soporific agent.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16000672     DOI: 10.1176/appi.psy.46.4.291

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  4 in total

Review 1.  Treatment options for sleep disturbances during alcohol recovery.

Authors:  J Todd Arnedt; Deirdre A Conroy; Kirk J Brower
Journal:  J Addict Dis       Date:  2007

2.  Acute akathisia with quetiapine: A case report and review of literature.

Authors:  Ruchita Shah; Sandeep Grover; Uma Maheshwari; Natasha Kate; Nidhi Malhotra
Journal:  Indian J Pharmacol       Date:  2010-12       Impact factor: 1.200

3.  A case series of serious and unexpected adverse drug reactions under treatment with cariprazine.

Authors:  Johannes Heck; Johanna Seifert; Dirk O Stichtenoth; Christoph Schroeder; Adrian Groh; Gregor R Szycik; Detlef Degner; Ivana Adamovic; Michael Schneider; Catherine Glocker; Eckart Rüther; Stefan Bleich; Renate Grohmann; Sermin Toto
Journal:  Clin Case Rep       Date:  2021-05-04

4.  Ziprasidone in the treatment of mania in bipolar disorder.

Authors:  Stephen E Nicolson; Charles B Nemeroff
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.